title: Gefitinib and non-small cell lunt cancer.
abstract: In comparison with first- or second-line chemotherapy, three reviews with meta-analyses of available trials confirm that gefitinib does not prolong overall survival and that it provokes severe adverse effects due to its epithelial toxicity.
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D000077143:Docetaxel; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011799:Quinazolines / Q000009:adverse effects*; D043823:Taxoids / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D043823:Taxoids; D000077143:Docetaxel; D066246:ErbB Receptors; D000077156:Gefitinib